Azacitidine Plus Lenalidomide Combination in Elderly Patients With Previously Treated AML and High-Risk MDS (VIREL2 Trial)

Trial Profile

Azacitidine Plus Lenalidomide Combination in Elderly Patients With Previously Treated AML and High-Risk MDS (VIREL2 Trial)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 May 2014

At a glance

  • Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms VIREL2
  • Most Recent Events

    • 16 Mar 2014 Trial status changed to discontinued as reported by ClinicalTrials.gov.
    • 01 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top